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ABSTRACT We investigated how complement activa-
tion promotes tissue injury and organ dysfunction
during acute inflammation. Three models of acute lung
injury (ALI) induced by LPS, IgG immune complexes,
or C5a were used in C57BL/6 mice, all models requir-
ing availability of both C5a receptors (C5aR and C5L2)
for full development of ALI. Ligation of C5aR and
C5L2 with C5a triggered the appearance of histones
(H3 and H4) in bronchoalveolar lavage fluid (BALF).
BALF from humans with ALI contained H4 histone.
Histones were absent in control BALF from healthy
volunteers. In mice with ALI, in vivo neutralization of H4
with IgG antibody reduced the intensity of ALI. Neutro-
phil depletion in mice with ALI markedly reduced H4
presence in BALF and was highly protective. The direct
lung damaging effects of extracellular histones were
demonstrated by airway administration of histones into
mice and rats (Sprague-Dawley), which resulted in ALI
that was C5a receptor-independent, and associated with
intense inflammation, PMN accumulation, damage/de-
struction of alveolar epithelial cells, together with release
into lung of cytokines/chemokines. High-resolution mag-
netic resonance imaging demonstrated lung damage,
edema and consolidation in histone-injured lungs. These
studies confirm the destructive C5a-dependent effects in
lung linked to appearance of extracellular histones.—
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The annual incidence of acute lung injury (ALI) and
acute respiratory distress syndrome (ARDS) approxi-
mates 200,000 cases in the United States, with mortality
rates around 20–40% (1–4). There are currently no
U.S. Food and Drug Administration (FDA)-approved
pharmacologic therapies for ALI/ARDS (5). Acute
lung injury (ALI) involves complement activation, as
indicated by attenuated severity in C5-deficient mice
following formation of immune-complexes (6, 7). Si-
lencing of complement component C5a receptor 1
(C5aR; CD88) in lung epithelial cells reduces the
severity of ALI (8). The pathology of ALI/ARDS is
characterized by an acute inflammatory response asso-
ciated with accumulation of polymorphonuclear neu-
trophils (PMNs), fibrin deposits, alveolar hemorrhage,
and pulmonary edema fluid (5, 9, 10). Lung dysfunc-
tion is aggravated by injury of alveolar epithelial and
vascular endothelial cells, leading to necrosis and apo-
ptosis (5, 11). Inflammatory mediators such as IL-1,
IL-6, TNF-, and leukotrienes, together with oxidants,
proteases, and complement activation products, are
thought to cause induction and progression of ALI/
ARDS (5, 7, 12, 13). The complement system is struc-
tured as a cascade of 25 proteins serving innate
immune defenses and homeostasis (14). Proteolytic
cleavage of complement proteins generates the anaphy-
latoxins, complement components C3a, C4a, and C5a,
the last displaying the highest inflammatory potency to
induce inflammation (15, 16). C5a frequently requires
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a costimulatory signal [e.g., lipopolysaccharide (LPS)
and N-formyl-Met-Leu-Phe] to trigger full biological
effects, such as neutrophil activation and chemotaxis.
In plasma, C5a is rapidly converted (t1/2: 5 min) to
biologically less active C5adesArg by carboxypeptidases
(17). C5a may be more stable in extravascular compart-
ments.
Both C5a and C5adesArg (with lower binding affinity)
are ligands for CD88, a member of the G-protein-linked
7-transmembrane domain receptor family (18, 19). C5a
interaction with C5aR initiates cytosolic Ca2 increases
and phosphorylation of MAP kinases in most cell types
(7). Expression of C5aR is found in high numbers within
the myeloid lineage, but T cells, as well as epithelial cells,
endothelial cells and fibroblasts, also express C5aR in
lower numbers (20–27).
C5a receptor 2 (C5L2; GPR77), shares 35% amino
acid identity with C5aR and was initially described as a
“default” receptor due to binding of both C5a and
C5adesArg without traditional signaling properties (28,
29). However, controversy has arisen as to whether
C5L2 was critically involved in proinflammatory func-
tions of C5a (30, 31). For example, both C5aR and
C5L2 modulate the inflammatory response during
polymicrobial sepsis (32). C5L2 and C5aR play distinct
roles in the C5a-dependent pathogenesis of experimen-
tal allergic asthma (33, 34). On the other hand, C5L2 is
dispensable for regulation of many but not all macro-
phage-derived cytokines by C5a (20, 35–37). Overall,
the sequence of events linking C5aR- and C5L2-medi-
ated acute inflammation with ensuing lung damage
and respiratory insufficiency is poorly understood.
The concept of neutrophil extracellular traps
(NETs) has recently attracted considerable attention
(38, 39). NETs are structures of extracellular histones
and DNA that ensnare and kill bacteria (38). The
formation of NETs is an orchestrated program involv-
ing activation of Raf/MEK/ERK signaling pathways
(40), chromatin hypercitrullination (41), assembly of
the multimeric NADPH oxidase complex, and genera-
tion of reactive oxygen species (ROS) (41, 42). NET
formation in the circulation is promoted by platelet-
leukocyte interactions and may subsequently trigger
coagulation and thrombosis (43, 44). It remains un-
clear how complement activation affects the extracellu-
lar appearance of NET components such as histones.
In this report, we address the gap in knowledge of
the molecular events by which C5a-induced inflamma-
tion progresses to tissue injury and loss of organ
function. Our findings suggest a critical involvement
for extracellular histones as mediators of acute pathol-




All procedures were performed in accordance with the U.S.
National Institutes of Health guidelines and the University
Committee on Use and Care of Animals (UCUCA), University
of Michigan. Male mice of the strain C57BL/6J (10–16 wk)
were from the Jackson Laboratories (Bar Harbor, ME, USA).
C5aR/ mice and C5L2/ mice (45), backcrossed for 10
generations on C57BL/6J, were bred and genotyped at the
University of Michigan. Sprague-Dawley rats (150–250 g)
were from Charles Rivers Laboratories (Wilmington, DE,
USA) or when implanted with carotid artery catheters were
from Taconic Farms (New York, NY, USA). All animals were
housed under specific-pathogen free conditions.
Human samples
The original ALI/ARDS study was approved by the Institu-
tional Review Board of the University of Michigan Health
System. In the current study, we used existing cryopreserved
cell-free and anonymous bronchoalveolar lavage fluid
(BALF) from mechanically ventilated patients that met crite-
ria for ALI or ARDS by the European Respiratory Society/
American Thoracic Society consensus definition (46). Details
of patient enrollment, study protocol and BALF sampling
techniques are described elsewhere (47). As controls, we used
BALF samples from healthy, age-matched, medication-free,
nonsmoking men and women. Western blotting of human
BALF was done as described below.
ALI models
For LPS-ALI, mice were anesthetized, and 40 l PBS contain-
ing 40 g LPS (Escherichia coli, O111:B4; Sigma-Aldrich, St.
Louis, MO, USA) injected intratracheally (i.t.; ref. 48). For
immunoglobulin G immune complex (IgGIC)-ALI, mice re-
ceived 125 g rabbit anti-BSA IgG i.t. (MP Biomedicals,
Solon, OH, USA), followed by 1 mg BSA i.v. (Sigma-Aldrich;
ref. 48). Sham-treated mice received 40 l PBS i.t. For
C5a-ALI, mice received rmC5a (endotoxin level:1.0 EU/g
protein; R&D Systems, Minneapolis, MN, USA). Histones for
intratracheal administration were purified from calf thymus
(Sigma-Aldrich). At the end of experiments, the lungs were
flushed with 1 ml PBS to obtain BALF. After centrifugation
(250 g, 5 min, 4°C), BALF cells were counted in a hemocy-
tometer (Hausser Scientific, Horsham, PA, USA), and cell-
free BALF was stored at 80°C until further analysis.
Measurement of histones, albumin, and mediator
concentrations in BALF
Alveolar permeability was assessed by quantitative detection
of mouse albumin in BALF by ELISA (Bethyl Laboratories,
Montgomery, TX, USA). For detection of multiple mediators,
the Bioplex Pro mouse cytokine assay, 23-Plex Group I
(Bio-Rad, Richmond, CA, USA) was used on a Luminex-
xMAP/Bioplex-200 System with Bioplex Manager 5.0 soft-
ware. The following mediators were analyzed: IL-1, IL-1,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70),
IL-13, IL-17, Eotaxin (CCL11), G-CSF, GM-CSF, IFN-, KC
(CXCL1), MCP-1 (CCL2), MIP-1 (CCL3), MIP-1 (CCL4),
RANTES (CCL5), and TNF-. The ELISA for detection of
histones (nucleosomes) in BALF was from Roche (Mann-
heim, Germany). Purified mixed calf thymus histones were
used to generate standard curves.
Western blotting
For analysis of extracellular histones, mouse lungs were
flushed with 4 	 1 ml PBS, BALF was centrifuged (400 g, 10
min, 4°C) and filtered (0.2-m syringe filters, Fisher Scien-
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tific, Waltham, MA, USA) and supernatants were stored at
80°C. BALFs from mice and humans were passed through
Amicon filter tubes (EMD Millipore, Billerica, MA, USA) with
a 30-kDa MW cutoff. The flow-through was then concentrated
using 10-kDa MW cutoff filter tubes to a volume of 50 l. This
procedure enriched the BALF samples for proteins from 10
to 30 kDa. Proteins (40 l of concentrated BALF) were
separated by electrophoresis, transferred to nitrocellulose
membranes, and probed with antibodies against histone H3
or histone H4 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA, and Millipore). Following staining with secondary anti-
bodies conjugated to horseradish peroxidase (Amersham,
Arlington Heights, IL, USA) the enzymatic reaction was
visualized using chemiluminescent substrate (Denville Scien-
tific, South Plainfield, NJ, USA). ImageJ 1.45s software (U.S.
National Institutes of Health, Bethesda, MD, USA) was used
for densitometry analysis of Western blots.
Flow cytometry
For detection of cell death we used the fixable viability dye
eFluor450, and intracellular calcium was assessed using the
calcium sensor dye eFluor514 (both from eBioscience, San
Diego, CA, USA). Staining protocols were according to man-
ufacturer’s instructions. Events (5	104) were acquired on a
BD LSR II flow cytometer (BD Biosciences, San Jose, CA,
USA), and data were analyzed using FlowJo 7.6.4 software
(TreeStar Inc., Ashland, OR, USA).
Microscopic imaging
Bright-field microscopy
Lungs were fixed in 4% formaldehyde overnight, and 3-m
paraffin-embedded sections were stained with hematoxylin
and eosin (H&E). Cytospins of BALF cells were stained with
modified Wright-Giemsa (Hema 3 Stain Set; Fisher Scien-
tific). Digital images (	40/0.9, 	100/1.4) were acquired
using an Olympus BH2 microscope (Olympus, Center Valley,
PA, USA).
Transmission electron microscopy
Lungs were fixed in 4% glutaraldehyde in 0.2 M cacodylate
buffer, postfixed for 1 h hour in 1% osmium tetroxide, rinsed
in cacodylate buffer, and dehydrated in ascending concentra-
tions of ethanol. Next, samples were transitioned through
propylene oxide and embedded in Epon epoxy resin (Mo-
mentive, Houston, TX, USA). Semithin sections were stained
with toluidine blue for tissue identification. Selected regions
of interest were ultrathin sectioned, 70 nm in thickness, and
poststained with uranyl acetate and lead citrate. They were
examined using a Philips CM100 electron microscope
(Philips, Amsterdam, The Netherlands) at 60 kV. Images were
recorded digitally using a Hamamatsu ORCA-HR digital
camera (Hamamatsu Photonics, Hamamatsu, Japan) and
AMT software (Advanced Microscopy Techniques Corp.,
Danvers, MA, USA).
Magnetic resonance imaging (MRI)
Animals were euthanized individually, and MRI examinations
were completed within 10 min postmortem. Mice lay prone in
a 7.0-T Agilent MR scanner (33 cm horizontal bore; Agilent,
Palo Alto, CA, USA). The radiofrequency coils used to scan
the thoracic region had a quadrature 35 mm volume for mice
and 63 mm volume for rats, respectively. Axial proton density/
T1-weighted images were acquired using a (fast) spin-echo
sequence with the following parameters. Mice: repetition
time (TR)/effective echo time (TE), 2000/11 ms; number of
echoes, 8; field of view (FOV), 30 	 30 mm; matrix, 256 	
128; slice thickness, 1 mm; number of slices, 15 contiguous;
and number of scans, 1 (total scan time 
4 min.). Rats:
TR/TE , 3000/17 ms; number of echoes, 8; FOV, 70 	 70 mm;
matrix, 256 	 128; slice thickness, 2 mm; number of slices, 20




A Buxco Max II and rodent bias flow supply part with
unrestrained whole-body plethysmography chambers (all
Buxco, Wilmington, NC, USA) were used. Rats were condi-
tioned to being placed in the chambers for 1 wk before
experiments. Physiological values from measured box flows
were calculated using the Epstein algorithm (BioSystem XA
for Windows 2.11 software; Buxco).
Blood gas analysis
Heparinized arterial blood (200–300 l) was drawn from rats
with carotid artery catheters and immediately analyzed on a
Radiometer ABL 835 Flex Blood Gas Analyzer (Diamond
Diagnostics, Holliston, MA, USA).
Cell culture
Alveolar epithelial cells, type II [mouse lung epithelial cell
line 12 (MLE-12) and mouse lung adenoma cell line 4
(LA-4)] were a gift from Dr. J. B. Weinberg (University of
Michigan). MLE-12 cells were cultured in RPMI1640 (10%
FCS, 100 U/ml penicillin-streptomycin, 2 mM l-glutamine, 10
mM HEPES, 10 nM -estradiol, 10 nM hydrocortisone, 5
g/ml transferrin, and 1	 insulin-transferrin-selenite) and
LA-4 cells in DMEM (15% FCS, 100 U/ml penicillin-strepto-
mycin, and 2 mM l-glutamine).
Antibodies and reagents
The following reagents were used: anti-Ly6G antibody (clone
RB6-8C5) and rat IgG2b isotype antibody (eBioscience),
neutralizing anti-histone H4 antibody (clone BWA3; ref. 49)
and mouse IgG1 isotype antibody (BioLegend), rmC5a
(R&D Systems), purified histones from calf thymus (Sigma),
histone H1 and histone H3 (Roche), and histone H4 (BPS
Bioscience, San Diego, CA, USA). The lactate dehydrogenase
(LDH) assay kit (Cayman Chemical, Ann Arbor, MI, USA)
was used according to instructions by the manufacturer.
Statistical analysis
GraphPad Prism 5.04 software (GraphPad, San Diego, CA,
USA) was used for statistical analysis. All values are expressed
as means, and error bars represent sem. Data sets were
analyzed by 2-tailed Student’s t test or 1-way ANOVA. In vitro
experiments were performed independently3 times, and in
vivo experiments used numbers of mice as indicated in the
figure legends. Values of P  0.05 were considered signifi-
cant.
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RESULTS
Dependency in ALI on both C5aR and C5L2
To investigate the respective roles of C5aR and C5L2 in
vivo in C57BL/6J mice, we used the genetically manip-
ulated (knockout) or nonmanipulated mouse strains in
three types of ALI (LPS, IgGIC, and C5a). The severity
of ALI was assessed by ELISA quantification of albumin
leakage in BALF as a marker in loss of epithelial/
endothelial (alveolar) barrier function. When C5aR/
and C5L2/ mice were compared to C57BL/6J wild-
type (Wt) mice after LPS-ALI, increases in alveolar
permeability were substantially reduced with genetic
absence of either C5a receptor (Fig. 1A). The severity
of lung injury was also reduced following IgGIC-ALI in
both C5aR/ and C5L2/ mice (Fig. 1B). Similar
patterns were obtained when ALI was induced by
intratracheal administration of recombinant mouse
C5a (C5a-ALI, Fig. 1C). The levels of alveolar albumin
in C5aR/ and C5L2/ mice after C5a-ALI remained
at concentrations comparable to C57BL/6J (Wt) mice
after PBS i.t. (sham treatment), whereas the same dose
of C5a resulted in extensive injury in C57BL/6J (Wt)
mice (Fig. 1C). BALF cells from C5a-ALI experiments
demonstrated the expected abundance of PMNs in
C57BL/6J (Wt) mice (Fig. 1D, top right panel). Many
fewer PMNs were present in BAL preparations obtained
from C5L2/ mice, and low numbers of alveolar
macrophages were present in samples from C5aR/
mice and in sham-treated C57BL/6J (Wt) mice (Fig.
1D). Quantitative counts of BALF PMNs after C5a-ALI
from the three mouse strains and Wt shams are shown
(Fig. 1E). Histopathology of lung sections from
C57BL/6J (Wt), C5aR/ and C5L2/ mice after
C5a-ALI demonstrated suppression of the inflamma-
tory response and injury with genetic deficiency of
either of the two C5a receptors (Fig. 1F).
Presence of extracellular histones in lungs from
humans with ALI
Recent findings have suggested a role of histones
released into the vascular compartment in the setting
of sepsis in subhuman primates (50). To determine the
presence of extracellular histones during ALI, we
screened cryopreserved cell-free BALF samples from
healthy volunteers (n12) and human patients with
ALI/ARDS (n21). Serial BALF samples from each
patient with ALI, using sequential time points (d 0–22)
after diagnosis of ALI/ARDS were available (n52
samples in total). The demographics of the study
population are shown in Supplemental Table S1. The
ALI/ARDS patients were critically ill, requiring me-
chanical ventilation. Bacterial pneumonia and sepsis
were most commonly identified as the precipitating
event leading to ALI/ARDS.
Examples of Western blot analysis for presence of H4
Figure 1. Essential roles of both C5aR and
C5L2 during the 3 models of ALI. A) Compar-
ison of alveolar permeability after LPS-ALI in
C57BL/6J (Wt), C5aR/, or C5L2/ mice.
Sham-treated mice received PBS i.t., ELISA for
BALF mouse albumin. B) Alveolar permeabil-
ity after IgGIC-ALI in C57BL/6J (Wt),
C5aR/, or C5L2/ mice (ELISA). C) Alve-
olar permeability after C5a-ALI in C57BL/6J
(Wt), C5aR/, or C5L2/ mice (ELISA). D)
Cytospins of BALF cells after C5a-ALI in
C57BL/6J (Wt), C5aR/, or C5L2/ mice,
Wright-Giemsa stains. E) PMN counts in BALF
after C5a-ALI in C57BL/6J (Wt), C5aR/, or
C5L2/ mice. F) Histopathology after C5a-
ALI in C57BL/6J (Wt), C5aR/, or C5L2/
mice (H&E stains). Duration of all ALIs shown was 8 h, and 500 ng i.t. rmC5a was used for C5a-ALI. Data from each
experiment shown are representative of n  7 mice/group. Error bars  sem. *P  0.05, **P  0.01, ***P  0.001;
Student’s t test.
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in BALF from patients with ALI are shown in Fig. 2A,
top panel. Figure 2A features a control (healthy volun-
teer) BALF showing absence of reactivity for histone 4
in the 15-kDa region. Patient 40589 BALF samples,
from a patient with ALI, were obtained at d 5, 14, and
21, revealing H4 reactivity near the 15-kDa position at
all time points. Patient 50131 BALF samples were also
consecutively obtained from a patient with ALI, and H4
presence was found on d 4, but not on d 8 and 21. It
would appear that H4 presence in BALF from patients
with ALI may be sustained or transient.
The presence of histone H4 in BALF from all sam-
ples of patients with ALI/ARDS and healthy volunteers
was determined by Western blotting, and results were
categorized as either positive or negative (Fig. 2A,
bottom panel). Analysis of n  12 samples of patients
with ALI/ARDS collected between d 0 and 5 after
diagnosis of ALI revealed that 50% of BALF samples
contained histone H4 (Fig. 2A, bottom panel, left bar).
Lower rates of histones were present in BALF samples
collected later than d 10 after ALI/ARDS diagnosis. In
BALF from healthy volunteers (control, n12) histone
H4 was not detectable (Fig. 2A, bottom panel).
Appearance of histones during experimental ALI is
dependent on C5aR, C5L2, and PMNs
To further assess the relevance of extracellular his-
tones, we analyzed murine BALF from three experi-
mental models of ALI. Histone H3 and histone H4 were
both detectable by Western blotting in cell-free BALF
from C57BL/6J mice after LPS-ALI, IgGIC-ALI, and
C5a-ALI (Fig. 2B, top panel). Both C5a receptors (C5aR
and C5L2) were required to generate extracellular
histones in C5a-ALI (Fig. 2B, bottom panel).
C5a is known to have chemotactic activity for PMNs
(7). To investigate what cell type is required for medi-
ating the appearance of extracellular histones during
Figure 2. Detection of extracellular histones during ALI in humans or mice. A) Top panel: Western blotting of histone H4 in
BALF from 2 humans with ALI/ARDS (40589; 50131) at sequential time points (4–21 d), a healthy volunteer (Ctrl BALF,
negative control), or recombinant H4 (rH4, positive control). Bottom panel: presence of histone H4 in BALF from humans with
ALI/ARDS and healthy volunteers (Western blotting). Percentage values of positive samples are indicated as bars for different
time points after diagnosis of ALI/ARDS, with total numbers of analyzed samples at top of each bar. B) Histones H3 and H4
in BALF after ALI models in Wt, C5aR/, or C5L2/ mice, 8 h; Western blotting. C) Top panel: histone H4 detection by
Western blotting in BALF of PMN-depleted Wt mice 8 h after C5a-ALI. Depletion of PMNs was achieved by monoclonal
anti-Ly-6G antibody (200 g i.p., 24 h) using isotype IgG as control. Bottom panel: absence of BALF PMNs after anti-Ly-6G
treatment. D) Densitometry of three independent Western blots for histone H4 in BALF of C5a-ALI (8 h) in Wt mice, when
PMNs were depleted as described above. E) ELISA for extracellular histones in BALF of sham-treated Wt mice or in Wt mice
after LPS-ALI, 8 h. F) Extracellular histones in BALF after IgGIC-ALI in Wt mice, 8 h; ELISA. G) Time course of histone release
in BALF following C5a-ALI, ELISA. H) Detection of extracellular histones in BALF of Wt, C5aR/ and C5L2/ mice after
C5a-ALI, 8 h; ELISA. Data are representative of the indicated numbers of human samples (A) or n 5 mice/group (B–H). Error
bars  sem. *P  0.05; Student’s t test.
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C5a-ALI, we depleted Ly-6G PMNs using monoclonal
antibody (Fig. 2C). The amount of histone H4 in
cell-free BALF after C5a-ALI was sharply reduced (Fig.
2C, top panel) when blood PMNs were depleted by
90% following treatment with anti-Ly-6G as compared
to IgG isotype control antibody (Fig. 2C, bottom
panel). Densitometry analysis of Western blot films of
PMN-depleted BALF showed a reduction of nearly 75%
in histone H4 (Fig. 2D).
To confirm our findings on release of extracellular
histones in the models of ALI, we used an ELISA
reactive for histones H1, H2A, H2B, H3, and H4.
Histones in BALF were abundant following induction
of ALI by LPS or immune complexes (Fig. 2E, F).
Time-ourse studies revealed that histones were present
in BALF as early as 4 h after C5a-ALI (Fig. 2G). Finally,
histones were greatly reduced (85–95%) after C5a-ALI
in C5aR/ mice and C5L2/ mice, as detected by
ELISA of BALF (Fig. 2H).
Blockade of extracellular histones attenuates severity
of ALI
To study the biological relevance of extracellular his-
tones during C5a-ALI, a neutralizing anti-histone H4
antibody was given simultaneously with intratracheal
instillation of C5a into C57BL/6J lungs (n15). The
control group (n16) received a matched preservative-
free isotype IgG1. Blockade of extracellular histone
H4 significantly (P0.0125) reduced by 
50% the
severity of alveolar barrier disruption following C5a-ALI
(Fig. 3A). Analysis of BALF from C5a-ALI experiments
with anti-histone H4 treatment also revealed greatly
reduced release of many proinflammatory mediators
(Fig. 3B), including TNF- and IL-6, as well as chemo-
kines, such as MCP-1, MIP-1, and MIP-1.
Extracellular histones are cytotoxic for alveolar
epithelial cells
To evaluate the mechanistic effects of extracellular
histones during lung injury, cultures of mouse MLE-12
and LA-4 cells were employed. Both cell lines are
Figure 3. Protective effects of neutralization of extracellular
histones during ALI. A) Reduced alveolar permeability dis-
turbances after C5a-ALI with treatment of neutralizing anti-H4
antibody (BWA3, 250 g i.v.  50 g i.t.) or isotype control
IgG1, 8 h; ELISA. B) Multiplex bead-based assay of media-
tors in BALF after C5a-ALI with treatment of anti-H4 antibody
or control IgG1, 8 h; ELISA. Only mediators with significant
differences (P0.05, 11 of 23 mediators) between groups are
shown. C5a was used as 500 ng/mouse i.t. Data were acquired
using n  15 mice/group. Error bars  sem. *P  0.05;
Student’s t test.
Figure 4. Cytotoxic effects of extracellular histones on alveolar
epithelial cells. A) LDH release from LA-4 and MLE-12 lung
alveolar epithelial cells exposed to purified histones (50 g/ml,
1 h), chromogenic assay. B) [Ca2]i staining in untreated (Ctrl)
LA-4 and MLE-12 cells or after histones (50 g/ml); flow
cytometry. C) Cell viability in LA-4 and MLE-12 cells exposed to
histones (50 g/ml, 1 h); cells were stained with a fixable cell
viability dye, eFluor450; flow cytometry. D) Cell viability of
MLE-12 cells after incubation with histone H1, histone H3,
histone H4, purified histones (all 50 g/ml), or untreated
controls, 1 h; flow cytometry. E) LDH concentrations in superna-
tant fluids from MLE-12 cells after 1 h incubation with histone
H1, histone H3, histone H4, or purified histones from calf thymus
(all 50 g/ml). F) LDH assay in MLE-12 cell culture supernatant
fluids. MLE-12 cells were left as untreated controls or incubated
for 60 min with purified histones (12.5 g/ml) premixed (30 min, 37°C) with either IgG1 isotype control antibody (250
g/ml) or anti-histone H4 antibody (BWA3; 250 g/ml). Data are representative of 3 independent experiments. Error
bars  sem. n.s., not significant. **P  0.01, ***P  0.001; Student’s t test.
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known to display phenotypic characteristics of type II
alveolar epithelial cells (e.g., surfactant production).
Incubation of either cell type with purified calf thymus
histones caused release within 1 h of LDH in superna-
tant fluids, indicating cell death (Fig. 4A). Flow cytom-
etry studies revealed a rise in intracellular Ca2 levels in
response to histone exposure in MLE-12 and LA-4 cells
at both 10 and 30 min (Fig. 4B). Consistent with the rise
of LDH, fluorescent staining techniques of MLE-12 and
LA-4 cells after the histone mixture indicated de-
creased cell viability (Fig. 4C). Distinct cytotoxic activi-
ties of histone H1, histone H3, and histone H4 were
seen at 60 min when compared to purified histones
(mixture of histone proteins; Fig. 4D, E). Notably, the
neutralizing anti-histone H4 antibody used in C5a-ALI
experiments (Fig. 3A, B) was also protective in cultures
of MLE-12 cells when incubated with purified histones
(Fig. 4F).
Extracellular histones compromise lung function by
tissue damage and promotion of inflammation
To further characterize the effects of extracellular
histones in vivo, purified histones were instilled into the
airways of Sprague-Dawley rats. Such treatments re-
sulted in immediate, severe respiratory disturbances
with compromised lung ventilation patterns, cyanosis
and occasional death. Serial blood gas analysis of rats
after intratracheal administration of histones compared
to sham treatment (PBS i.t.) showed a substantial
acidification in arterial pH (Fig. 5A) together with
greatly elevated carbon dioxide tension (pCO2) (Fig.
5B). In addition, arterial oxygen tension and arterial
oxyhemoglobin saturation (SaO2) were severely re-
duced after histone administration (Fig. 5C, D). Values
for arterial base excess (BE; 0.80.6 vs. 0.80.8 mM)
and arterial bicarbonate (HCO3
: 26.00.5 vs. 25.40.5
Figure 6. Whole-body plethysmography fol-
lowing airway administration of histones.
Sprague-Dawley rats received purified his-
tones (50 g/g body weight i.t.) or PBS i.t
(sham treatment). Respiration was monitored
before the intervention and at intervals dur-
ing the following 24 h: A) Typical box flows
(raw data) during whole-body plethysmogra-
phy of rats after airway exposure to purified
histones compared to sham-treated rats.
B) Respiratory rates. C) Minute ventilation.
D) Inspiratory flow times. E) Inspiratory
times. F) Expiratory flow times. G) Total respiratory cycle. Data are representative of n  4 rats/group. Error bars 
sem. *P  0.05, **P  0.01, ***P  0.001; Student’s t test.
Figure 5. Administration of extracellular histones into airways induces severe disturbances in alveolar-capillary gas exchange.
Purified histones (50 g/g body weight) were administered i.t. to Sprague-Dawley rats with implanted carotid artery catheters.
Sham-treated animals only received PBS i.t. Serial blood gas analyses were performed at baseline and at intervals following the
intervention. A) Arterial pH. B) Arterial pCO2. C) Arterial pO2. D) Arterial oxygen saturation, SatO2. Data are representative
of n  4 rats/group. Error bars  sem. *P  0.05, **P  0.01, ***P  0.001; Student’s t test.
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mM) remained within normal limits in both groups (data
not shown). Collectively, arterial blood gas analyses after
histone treatment reflected acute disturbances in gas
exchange across the alveolar-capillary membranes, lead-
ing to severe respiratory acidosis.
Lung ventilation was also assessed by whole-body
plethysmography. Box flows (raw data) of lung excur-
sions from rats following histone administration dis-
played obvious functional abnormalities (Fig. 6A).
There were steep increases in respiratory rates (Fig.
6B), minute ventilation (Fig. 6C), and inspiratory flow
(Fig. 6D) in response to intratracheal purified histones.
In accordance with the increased respiratory rates,
inspiratory times (Fig. 6E), expiratory times (Fig. 6F)
and total respiratory cycle times (Fig. 6G) were greatly
diminished. The abnormalities in lung ventilation pat-
terns (Fig. 6) persisted for 24 h and may in part account
for a compensatory normalization of blood gases at the
later time points (Fig. 5).
The administration of calf thymus histones into airways
of C57BL/6J mice resulted in dose-dependent disruption
of the alveolar permeability barrier (Fig. 7A). The peak in
alveolar albumin leakage occurred 8 h after histone
instillation (Fig. 7B). Leukocytes [white blood cells
(WBCs)] were  80% PMNs, peaking at 8 h (Fig. 7C).
The early suppression of WBCs at the 1 and 3 h time
points may be explained by the rapid cytotoxic effects
of histones, triggering a wave of migration of inflam-
matory cells into the alveolar compartment at time
points6 h (Fig. 7C). The cytotoxicity of histones given
via the airways was documented by an early increase of
LDH levels in BALF (Fig. 7D). A time-dependent
Figure 7. Induction of acute inflammation in lungs by extracellular histones. A) Disruption of alveolar permeability in C57BL/6J
mice after intratracheal deposition of purified histones at different doses, 8 h; BALF albumin ELISA. B) Time course for alveolar
permeability after exposure to purified histones (100 g i.t.), C57BL/6J mice; ELISA. C) White blood cell (WBC) content
(mainly PMNs) in BALF from C57BL/6J mice after purified histones from the experiment described in B. D) LDH in BALF from
the experiment in B; chromogenic assay. E) Mediators in C57BL/6J mice after treatment with purified histones (100 g i.t.),
with BALF harvested at different time points; multiplex bead-based assay. Data are representative of n  5 mice/group. Error
bars  sem. *P  0.05, **P  0.01, ***P  0.001; Student’s t test.
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release of several proinflammatory cytokines (IL-1,
IL-6, and TNF-) and chemokines (KC, MCP-1, MIP-1,
MIP-1, and RANTES) occurred following administra-
tion of histones i.t. (Fig. 7E). Several of these mediators,
such as IL-1, IL-6, and TNF-, are known to be
associated with development and progression of ARDS
in humans (4, 5). Administration of histone extracts to
C5aR/ mice did not result in less severity of ALI or
less PMN influx, suggesting that there is no feedback of
extracellular histones on complement activation (Sup-
plemental Fig. S1). Therefore, once formed, histones
do not require C5aR or C5L2 for induction of ALI.
High-resolution MRI was employed for imaging of
lungs following administration of histones i.t. (Fig. 8A, B).
Axial thoracic images showed bilateral signal-intense lung
infiltrates consistent with pulmonary edema in both
C57BL/6J (Wt) mice and Sprague-Dawley rats (Fig. 8A, B,
arrowheads), which were not seen in sham-treated con-
trols. The technical imaging quality was superior in
Sprague-Dawley rats as compared to smaller scale mouse
lungs. More detailed MRI scans (z stacks) of rat lungs are
available in Supplemental Videos S1 and S2.
Histopathologic examination of lungs after histone
instillation showed accumulation of PMNs in alveolar
spaces, capillary congestion, and areas of intra-alveolar
hemorrhage, fibrin deposits and thrombi (especially in
large veins), together with exfoliation of bronchial epithe-
lial cells and increased mucous production by epithelial
cells (Fig. 8C). Transmission electron micrographs dem-
onstrated normal vasculature and airway architecture in
sham-treated mice (Fig. 8D, top and bottom left panels).
Following lung exposure to histones, intra-alveolar PMNs,
erythrocytes, fibrin deposits (arrow heads) and epithelial
cell injury with bleb formation (arrow) were observed
(Fig. 8D, top and bottom right panels).
In summary, ALI induced by LPS, IgGIC or C5a
caused release of histones in the distal alveolar com-
partment. Histones were directly cytotoxic for various
lung cell types, especially alveolar epithelial cells, pro-
moting subsequent ALI and persistent inflammation.
DISCUSSION
The occurrence of tissue injury and cell death is a
common feature of many acute and chronic inflamma-
tory diseases, including those involving the lung. This
phenomenon translates into organ dysfunction that
may be followed by either tissue remodeling with
fibrosis or persistent organ failure. Our findings char-
acterize the molecular events connecting anaphyla-
toxin C5a and its receptors with the manifestations of
organ failure occurring in animals or patients with
ALI/ARDS (Fig. 9).
Figure 8. Extracellular histones mediate lung consolidation and acute histopathology in lungs. A) High-resolution MRI of lungs
from C57BL/6J mice after PBS i.t. (sham treatment) or purified histones (20 g/g body weight), 6 h. Arrowheads indicate
signal-intense intrapulmonary areas consistent with consolidation of lung tissue; axial proton density/T1-weighted images; slice
thickness: 1 mm. B) High-resolution MRI of lungs from Sprague-Dawley rats 6 h after PBS i.t. (sham) or purified histones (20
g/g body weight). Arrowheads indicate signal-intense intrapulmonary areas of lung infiltrations; slice thickness: 2 mm. C)
Histopathology of lungs from C57BL/6J mice after treatment with purified histones (20 g/g body weight i.t.) compared to
sham-treated lungs, 6 h, H&E staining. D) Transmission electron microscopy of normal lungs (sham treatment) from C57BL/6J
mice compared to lungs after exposure to purified histones (100 g i.t.), 8 h; 	2000. Arrow indicates blebbing of type II
pneumocyte; arrowheads indicate fibrin deposits. Data are representative of n  5 animals/group.
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C5a orchestrates immediate innate immune defense
mechanisms to facilitate clearance of pathogens and
harmful noninfectious agents [damage-associated mo-
lecular patterns (DAMPs) and alarmins]. To our sur-
prise, instillation of recombinant C5a into the airways
of mice did not require a costimulus to initiate damag-
ing inflammation, consistent in part with findings that
used rabbits and human C5a purified from activated
serum decades ago (51). Injection of C5a has been used
recently to induce peritonitis in mice (52). C5L2, in
addition to C5aR, is required for full C5a-dependent
activation of signaling pathways in Ly-6G PMNs (30).
Genetic deficiency of either C5aR or C5L2 markedly
reduced the intensity of ALI in all models tested, as
reported herein. This may suggest functional coopera-
tion between C5aR and C5L2 (53), implying that C5aR
cannot compensate for the absence of C5L2, and vice
versa. We were unable to confirm an earlier report of
anti-inflammatory properties of C5L2 during IgGIC-
ALI (45). These apparent discrepancies may be ex-
plained by variations in methodologies regarding dos-
ing and species (chicken vs. bovine) of the albumins
and anti-albumin antibodies, as well as differences in
the genetic backgrounds of C5L2-deficient mice. Nota-
bly, our findings are in accordance with a recent report
describing proinflammatory roles of C5L2 in the con-
text of experimental asthma (33).
Our findings suggest that the detrimental effects of
complement activation during experimental lung in-
jury are associated with release of histones into the
lung. In addition, we also show the presence of extra-
cellular histones in BALF in approximately half of
human patients with ALI/ARDS. In our experiments,
histones outside of cells were highly cytotoxic for
alveolar epithelial cells, promoting tissue damage and
inflammation; such effects were reversed by blockade
of histones in vivo. Emerging evidence suggests that
complement activation may trigger the appearance of
nucleosomes (histones/DNA) after trauma and appear-
ance of NETs during viral infection (54, 55). Of note,
several other endogenous cytotoxic factors are known.
The intravital lysis of erythrocytes or muscle fibers with
release of free hemoglobin or myoglobin often results
in nephrotoxicity (56). Recently, the leakage of com-
ponents from mitochondria to areas beyond has been
linked to induction of inflammation (57). Another
group has suggested that appearance of extracellular
histones (in plasma) is associated with death in exper-
imental sepsis in rodents and subhuman primates (50).
Extracellular histones in the vasculature were found to
be cytotoxic for the endothelium (50). A recent study
has linked circulating histones with trauma-associated
ALI/ARDS (58).
In the era following the discovery of penicillin,
histone extracts were recognized to have bactericidal
activity in vitro (59). Recombinant histone H4 possesses
antimicrobial activity against Staphylococcus aureus and
Propionibacterium acnes (60). Histones can be released
from dying nonimmune cells and inhibit uptake of
apoptotic cell particles by phagocytes (61, 62). The
bactericidal potential of histones may be advantageous
to the formation of NETs that capture and remove
bacteria as part of innate immune defenses triggered by
TLR4 on platelets (38, 43, 63). On the other hand,
NETs directly promote cell death of nonleukocytic cells
(64), which may trigger an additional release of his-
tones from these cells. Histone H3 has been reported to
interfere with the phagocytosis of apoptotic cells by
macrophages (62). These concepts are shown in Fig. 9.
The effects of extracellular histones in murine models
of liver injury are dependent on TLR2 and TLR4
receptors (65). However, extracellular histones have
direct cytotoxic activities not only on eukaryotic cells
but also prokaryotes, the latter not expressing Toll-like
receptors. In our experiments lung injury induced by
extracellular histones was also reduced in TLR4/
mice (data not shown). In addition to these mecha-
nisms, we present novel evidence that full release of
extracellular histones requires the presence of C5aR
and C5L2 receptors (Fig. 2).
Extracellular histones appear to undergo cleavage by
activated protein C (APC), resulting in their inactiva-
tion (50). APC was the only drug approved by the FDA
for the treatment of sepsis until its recent withdrawal
from the market. Therefore, more effective strategies
for the blockade of extracellular histones are needed.
Death of alveolar epithelial cells during lung inflamma-
tion may result from or augment the release of cyto-
toxic histones which subsequently trigger adjacent cells
(endothelial, alveolar epithelial cells) to undergo dis-
integration. During ALI, pharmacologic enhancement
of apoptosis may induce less cytotoxic outcomes due to
reduced release of histones. Whether histones could be
Figure 9. Schematic overview of the proposed pathophysio-
logic events in ALI. LPS and IgG immune complexes trigger
complement activation, including release of C5a. Ligation of
C5a with C5aR and C5L2 activates PMNs and macrophages
for mediating the formation of NETs in the case of PMNs.
Extracellular histones derived from NETs or dying nonleuko-
cytic cells perpetuate detrimental cell/tissue injury, resulting
in greater severity of ALI.
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reduced by transfusion of mesenchymal stem cells,
which have been proposed as a novel treatment for ALI,
remains a matter of speculation (66). The concept that
complement activation via C5aR and C5L2 triggers
release of products of nucleosomes (such as histones),
resulting in a circle of tissue injury and inflammation,
in the setting of ALI and other diseases, deserves
further study.
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